An observational study in Rectal Cancer, Ileostomy; Complications and Quality of Life, sponsored by The Hospital of Vestfold. Recruiting at 18 sites in Norway. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2023-05-24.
Sponsored by The Hospital of Vestfold · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Rectal Neoplasms with a site in Norway — 6 open to participants now, 12 under way, 3 of them phase 3. Rectal Neoplasms · Norway.
Among the 25 studies in Rectal Neoplasms with a site in Norway, this one is the 3rd largest by planned enrollment of the 11 observational ones that give a count, is one of 5 that started in 2022, is one of 11 observational ones, reaches primary completion later than 5 of the 11 other live ones, and was the 19th registered.
2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.
Browse Rectal Neoplasms studies →6 of the 25 studies in Rectal Neoplasms with a site in Norway are open now. Recruiting first, the newest first:
Haukeland University Hospital · Sites in Norway
Ages 18+
San Raffaele University · Sites in Norway, United States, Finland and 3 more countries
Ages 18–49 · Healthy volunteers
Oslo University Hospital · Sites in Norway
Ages 18+
Catharina Ziekenhuis Eindhoven · Sites in Norway, Belgium, Netherlands and 2 more countries
Ages 18+
Helse Stavanger HF · Sites in Norway
Ages 18+
A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →
Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 5 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 161 across 499 observational studies indexed under Rectal Neoplasms.
Median enrollment 106 across the 13 interventional studies, 192 across the 11 observational. Of the 12 that completed or were terminated, 1 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 25 have an industry lead sponsor. The 10 most frequent:
The Hospital of Vestfold is the lead sponsor of 16 studies on the registry; 2 are open to participants now.
The Hospital of Vestfold has 1 study filed under Rectal Neoplasms — fewer than ten, so there is no comparison to draw.
3 of the studies in Rectal Neoplasms with a site in Norway that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04726800Anna MartlingCirculating Tumour DNA (ctDNA) as a Prognostic and Predictive Marker in Colorectal Cancer - a Pilot Study | 2026-12 |
| NCT05883800Haukeland University HospitalTotal Neoadjuvant Treatment Combined With Adaptive Radiotherapy for Rectal Cancer | 2026-12-31 |
| NCT04512937Oslo University HospitalComputer Navigation-assisted Surgery for Locally Advanced and Recurrent Rectal Cancer | 2027-09-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 25 studies in Rectal Neoplasms with a site in Norway, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The Norwegian Stoma Trial is an open-label multicenter trial investigating the use of stomas, both diveriting and permanent, in the surgical treatment of rectal cancer. The objective is to compare the chosen strategy to surgical complications, health realted quality of life and length of stay.
In this national, multicenter study the study group will investigate whether patients with rectal adenocarcinoma undergoing a resection with an anastomosis will benefit from a diverting stoma or not, by studying how choice of surgery affects complications. In addition the study group will investigate complication rates and HRQoL among patients receiving a permanent colostomy and compare this to patients who have received an anastomosis. The investigators know that there are different approaches to the use of stomas (both permanent and diverting) between different hospitals. The investigators aim to discover potential differences in complication rates, length of stay and HRQoL among these patients and compare this to the chosen strategy. Health related quality of life will be measured using the EORTC CR 29 and EORTC CR 30 questionnares. Bowel function will also be monitored using the LARS (low anterior resection syndrome) score.
All adult patients undergoing a formal resection for rectal cancer will be asked to participate as long as they fit the eligibility criteria
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients operated for rectal cancer with rectal resection and diverting stoma.
Procedure: Rectal resection with diverting stoma
Patients operated for rectal cancer with rectal resection without diverting stoma.
Procedure: Rectal resection without diverting stoma
Patients operated for rectal cancer with rectal resection with primary colostomy.
Procedure: Rectal resection with permanent colostomy
Patients in this group will receive a rectal resection with an anastomosis and also a diverting stoma will be created
Patients in this group will receive a rectal resection with an anastomosis and no diverting stoma will be created
Patients in this group will receive a rectal resection and a permanent colostomy will be created
Surgical complications graded as Accordion grade 3 or more
The study group will investigate whether patients undergoing rectal resection with an anastomosis with a diverting stoma will have higher complication rates compared to patients who do not recieve a diverting stoma.
Time frame: Measured one year after the primary surgery
Total length of hospital stay
Number of days admitted at hospital. The study group will investigate whether patients undergoing rectal resection with an anastomosis with a diverting stoma will have a higher number of days admitted to hospital compared to patients who do not recieve a diverting stoma.
Time frame: Measured one year after the primary surgery
Generic health related quality of life measured by the European Organization for Research and Treatment of Cancer (EORTC) C30 questionnaire
Generic health related quality of life is measured using the EORTC C30 questionnaire. Investigate whether patients receiving a rectal resection with a primary colostomy have poorer health related quality of life compared to patients receiving an anastomosis.
Time frame: One year after the primary surgery
Bowel function measured by the Low Anterior Resection Syndrome (LARS) score
Bowel function is measured using the Low Anterior Resection Syndrome score. The score ranges from 0 to 42 points The higher the score, the worse the bowel function. Investigate whether patients undergoing rectal resection with an anastomosis with a diverting stoma will have higher LARS scores compared to patients who do not recieve a diverting stoma.
Time frame: One year after the primary surgery
Surgical complications graded as Accordion grade 3 or more
Investigate whether patients receiving a rectal resection with a primary colostomy have lower complication rates compared to patients receiving an anastomosis
Time frame: Measured one year after the primary surgery
Generic health related quality of life measured by the European Organization for Research and Treatment of Cancer (EORTC) C30 questionnaire.
Generic health related quality of life is measured using the EORTC C30 questionnaire. Investigate whether patients undergoing rectal resection with an anastomosis with a diverting stoma will have poorer health related quality of life compared to patients who do not recieve a diverting stoma.
Time frame: One year after the primary surgery
Disease specific health related quality of life measured by the European Organization for Research and Treatment of Cancer (EORTC) CR29 questionnnaire
Disease specific health related quality of life measured by the EORTC CR29 questionnnaire. Investigate whether patients undergoing rectal resection with an anastomosis with a diverting stoma will have poorer health related quality of life compared to patients who do not recieve a diverting stoma.
Time frame: One year after the primary surgery
Disease specific health related quality of life measured by the European Organization for Research and Treatment of Cancer (EORTC) CR29 questionnnaire.
Disease specific health related quality of life measured by the EORTC CR29 questionnnaire. Investigate whether patients receiving a rectal resection with a primary colostomy have poorer health related quality of life compared to patients receiving an anastomosis.
Time frame: One year after the primary surgery
Plan to share: Undecided
No publications or documents are linked to this record.
Started Sep 2022 (actual). Primary completion is estimated for Aug 2025, 35 months after the start.
Of 214 non-industry observational studies under Rectal Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 118. This study's planned 35 months is below that.
Counting every sponsor, half of 229 studies reached it within 45 months; a quarter within 24 and three quarters within 116.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Hospital of Vestfold